Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Pascal Touchon, insider at Atara Biotherapeutics
Pascal Touchon Insider Alerts

Get notified the next time Pascal Touchon buys or sells Atara Biotherapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Pascal Touchon Insider Information

With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Pascal has committed his career to transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence.

Previously Global Head, Cell & Gene and member of the Oncology Executive Committee at Novartis Oncology, he oversaw the Oncology Cell & Gene unit and had responsibility for the unit’s financial performance and its activities, including the global launch of KYMRIAH® (tisagenlecleucel), securing regulatory approval and reimbursement in major markets, expanding global CAR T manufacturing and technical operations, overseeing multiple new clinical studies, and building a strong leadership team.

Prior to that, he served as Global Head, Strategy, Business Development, Oncology at Novartis, where he was responsible for early commercial strategy, portfolio management, therapeutic integrity and established medicines, disruptive technologies, diagnostics, business development and external collaborations, and served as a member of the Oncology Executive Committee. Pascal has also held key leadership roles in research, marketing, general management, and business development at companies including Servier, Glaxo-Wellcome and Glaxo, Sanofi. He has also been a board member of Genoptix and Navigate Biopharma Services (Novartis companies) and Cogen Therapeutics (a Flagship Pioneering company).

Pascal holds a doctorate in veterinary medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Superieures Specialisees (DESS) in management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Beyond his passion for science and business, Pascal enjoys traveling with his family around the world, wine tasting with friends, watching rugby, and reading.

What is Pascal Touchon's net worth?

The estimated net worth of Pascal Touchon is at least $5.76 million as of August 17th, 2021. Dr. Touchon owns 336,891 shares of Atara Biotherapeutics stock worth more than $5,757,467 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Touchon may own. Learn More.

What is Pascal Touchon's salary?

As the CEO of Atara Biotherapeutics, Inc., Dr. Touchon earned a total compensation package of $5,285,827.00 in 2020. Dr. Touchon earned a salary of $654,857.00, a bonus of $422,500.00, stock awards of $2,235,600.00, options awards of $1,959,208.00, and other compensation of $13,662.00.

How do I contact Pascal Touchon?

The corporate mailing address for Dr. Touchon and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (650) 278-8930 and via email at [email protected]

Has Pascal Touchon been buying or selling shares of Atara Biotherapeutics?

Over the course of the past ninety days, Pascal Touchon has sold $143,842.00 in Atara Biotherapeutics stock. Most recently, Pascal Touchon sold 8,402 shares of the business's stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $17.12, for a transaction totalling $143,842.24.

Who are Atara Biotherapeutics' active insiders?

Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider).

Are insiders buying or selling shares of Atara Biotherapeutics?

During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 34,354 shares worth more than $500,396.31. During the last year, insiders at the biotechnology company sold shares 29 times. They sold a total of 191,548 shares worth more than $5,225,968.51. The most recent insider tranaction occured on November, 16th when CEO Pascal Touchon sold 8,402 shares worth more than $143,842.24. Insiders at Atara Biotherapeutics own 3.8 % of the company.

Information on this page was last updated on 11/16/2021.

Pascal Touchon Insider Trading History at Atara Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2021Sell8,402$17.12$143,842.24View SEC Filing Icon  
8/17/2021Sell8,223$12.53$103,034.19336,891View SEC Filing Icon  
8/18/2020Sell4,807$12.09$58,116.63260,037View SEC Filing Icon  
6/25/2020Sell12,135$12.92$156,784.20264,844View SEC Filing Icon  
See Full Table

Pascal Touchon Buying and Selling Activity at Atara Biotherapeutics

This chart shows Pascal Touchon's buying and selling at Atara Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atara Biotherapeutics Company Overview

Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $17.09
Low: $16.83
High: $18.26

50 Day Range

MA: $17.27
Low: $14.70
High: $19.89

2 Week Range

Now: $17.09
Low: $11.81
High: $28.20


620,404 shs

Average Volume

768,391 shs

Market Capitalization

$1.51 billion

P/E Ratio


Dividend Yield



Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!